Telix Pharmaceuticals is a dynamic, fast-growing radiopharmaceutical company with offices in Australia (HQ), Belgium, Japan, Switzerland, and the United States. Our mission is to deliver on the promise of precision medicine through targeted radiation. At our core, we exist to create products that seek to improve the quality of life for people living with cancer and rare diseases. You will be supporting the international roll-out of our approved prostate cancer imaging agent and helping us to advance our portfolio of late clinical-stage products that address significant unmet need in oncology and rare diseases.

See Yourself at Telix

As a Territory Account Manager, you will be responsible for driving sales growth and strengthening client relationships within your designated region. You will identify new business opportunities, manage existing accounts, and promote our portfolio of radiopharmaceutical products. This position requires strategic thinking, strong relationship management, and a deep understanding of the radiopharmaceutical and healthcare industries.

Strong preference for candidates to be local to the following areas: Providence, RI, Hartford, CT., Albany, NY

Key Accountabilities:

Sales and Business Development

Identify, qualify, and secure new business opportunities within the assigned territory.
Develop and execute strategic sales plans to meet or exceed territory goals.
Conduct market analysis to understand industry trends, emerging technologies, and competitive activities.

Account Management

Build and maintain long-term relationships with key clients and stakeholders.
Provide exceptional customer service by addressing inquiries, concerns, and product needs promptly.
Collaborate with internal teams to ensure client satisfaction and seamless service delivery.

Product Expertise

Maintain a deep understanding of the features, benefits, and clinical value of our radiopharmaceutical products.
Deliver effective product presentations, demonstrations, and training sessions to healthcare professionals.

Reporting and Analysis

Prepare and deliver regular sales reports, forecasts, and performance updates to management.
Accurately record all activities and customer information in Salesforce.com.
Analyze sales data to identify growth opportunities and areas for performance improvement.

Compliance and Ethics

Adhere to all company policies, procedures, and regulatory guidelines.
Stay current with industry regulations and communicate relevant updates to stakeholders.

Position Requirements

Education and Experience

4 year degree from an accredited university resulting in a BA/BS degree.
Minimum 5 years of experience in medical, pharmaceutical, or diagnostic sales within hospital or academic settings.
Demonstrated experience engaging in grand rounds, tumor boards, P&T committees, and multidisciplinary clinical presentations.
Proven track record of successfully launching new products and achieving or exceeding sales targets.
Experience in Nuclear Medicine, Oncology, or Urology sales strongly preferred.
Strong understanding of the U.S. reimbursement landscape and healthcare sales processes.
Skilled in developing and executing sales operating plans aligned with corporate goals.
Experienced in project management, including budgeting, contracting, and timeline management.
Ability to quickly learn and communicate complex clinical or technical information.
Excellent written, verbal, and presentation skills.
Highly organized, proactive, and results-driven team player.

Key Capabilities:

Commitment to excellence: Take pride in your work and consistently strive for excellence in everything you do
Results-oriented: Driven to achieve goals and objectives, with a strong focus on delivering measurable results
Creativity and innovation: Possess a willingness to think outside the box and come up with unique and creative solutions to challenges
Strong communication skills: Able to communicate effectively with colleagues and stakeholders at all levels, using clear and concise language
Collaboration: Work effectively as part of a team, actively sharing knowledge and expertise to achieve common goals
Resilience: Demonstrate the ability to bounce back from setbacks and persevere in the face of challenges
Inclusive mindset: Demonstrate an understanding and appreciation for diversity, and actively work to create an inclusive environment where everyone feels valued and respected
Adaptability: Comfortable working in a dynamic environment, able to adjust to changing priorities, and willing to take on new challenges
Ethical behavior: Act with integrity and demonstrate a commitment to ethical behavior in all interactions with colleagues and stakeholders
Continuous learning: Show a commitment to ongoing learning and professional development, continually seeking out opportunities to expand your knowledge and skills

At Telix, we believe everyone counts, we strive to be extraordinary, and we pursue our goals with determination and integrity. You will be part of an engaged and supportive group of colleagues who all have a shared purpose: to help people with cancer and rare diseases live longer, better quality lives. Being a Telix employee means being a part of a unique, global, interdisciplinary team working to deliver what's next in precision medicine. We have hybrid and remote employees located all around the world. We offer competitive salaries, annual performance-based bonuses, an equity-based incentive program, generous vacation, paid wellness days and support for learning and development.

Telix Pharmaceuticals is an equal opportunity employer. We evaluate qualified applicants without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, veteran status, and other legally protected characteristics.

VIEW OUR PRIVACY POLICY HERE

About the company

Telix Pharmaceuticals develops and commercializes diagnostic and therapeutic products that use targeted radiation to diagnose and treat cancer and rare diseases. Its pipeline covers urologic oncology (prostate and kidney cancers), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. The treatments work by delivering targeted radiation to diseased tissues, enabling more precise decisions for treatment and allowing for personalized therapy. The company differentiates itself through a global, robust supply chain and a focus on integrating diagnostic and therapeutic options to address unmet medical needs, along with strong commitments to patient care, ethical practices, and environmental responsibility. Telix’s goal is to improve quality of life and outcomes for patients by providing targeted, clinically meaningful diagnostic and therapeutic solutions that support better treatment decisions and personalized care.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Melbourne, Australia

Founded

2015

Get referred to Telix Pharmaceuticals

See people who can refer or advise you

Simplify's Take

What believers are saying

FDA approved Pixclara on September 13, 2026, opening Telix's first brain-cancer imaging market.
H1 2026 revenue reached $477 million, up 22%, with EBITDA rising 146%.
BiPASS enrolled 350 patients and Telix aligned with FDA on a U.S. NDA pathway.

What critics are saying

Telix still depends on FDA manufacturing acceptance for Zircaix resubmission in 2026.
The $2.35 billion ITM deal brings dilution, debt, and integration strain through 2027.
Novartis, with Lutathera and Pluvicto, attacks Telix in GEP-NETs and prostate therapy.

What makes Telix Pharmaceuticals unique

Telix sells both diagnostics and therapies across the same radiopharmaceutical platform.
Illuccix and Gozellix give Telix a commercial prostate imaging franchise in 24 countries.
ITM adds isotope manufacturing, distribution, and lutetium-177 supply across more than 65 countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Annual Performance Bonus
Equity-Based Incentive Program
Paid Vacation
Paid Wellness Days
Hybrid Work Options
Remote Work Options

Growth & Insights and Company News

6 month growth

1 year growth

16%

2 year growth

Capital Brief

Oct 21st, 2026

SpaceX Q3 earnings smash expectations as AI revenue soars.

SpaceX Q3 earnings smash expectations as AI revenue soars. Stocks Slide Telix Pharmaceuticals shares slump despite Q3 revenue growth. 6:20pm today The news: Shares in Telix Pharmaceuticals tumbled in morning trade despite the global biopharmaceutical company reporting a 19% year-on-year increase in third quarter group revenue to USD245 million ($349 million). Shares slumped 7.3% to $14.60 at 11:54am AEDT. The context: The company saidthe revenue growth was supported by its precision medicine division, which recorded a 30% year-on-year jump to USD201 million. This was primarily driven by sustained demand for its flagship imaging products Gozellix and Illuccix. The strong performance follows the FDA approval of its brain cancer (glioma) imaging agent, Pixclara in the US earlier in September, with first commercial sets of patients successfully dosed in early October. Telix expects to generate total full-year revenue and other income of over USD1 billion, tracking toward the upper end of its core product guidance of between USD950 million and USD970 million. The source: ASX Get Letter of Intent in your inbox. The jobs marketplace is hoping to reel in $700m by selling non-core parts of its investment portfolio. At current valuations, that may prove a hard sell. Hugo Mathers · 9:31pm today Two of Australia's established data centre companies insist there is still strong support for proven players in their industry despite Firmus' pulled IPO. Brandon How · 10:41pm yesterday Private equity is finding treasure in the ASX's unglamorous businesses, with a flurry of takeover deals on Monday for bins, pipes and car fleets. Hugo Mathers · 19 October 2026

Daily Dispatch

Oct 20th, 2026

Philadelphia cyclotron to give Telix a dedicated source of rare alpha isotope.

Philadelphia cyclotron to give Telix a dedicated source of rare alpha isotope. Telix has partnered with a new Franco-Belgian venture to produce astatine-211 in the United States. The isotope is scarce but is being studied closely as a new way to deliver radiation straight to cancer cells. The collaboration is with Ekalia, a joint venture between Belgian cyclotron maker IBA and French nuclear group Framatome. The first of IBA's alpha-beam cyclotrons will be installed and run at Telix's RLS Radiopharmacies site in Trevose, near Philadelphia. Astatine-211 is an alpha-emitting radioisotope under investigation for targeted alpha therapy. In this approach, a drug carries a radioactive payload directly to a tumour. The partners describe the isotope as promising for new cancer treatments, but say limited production capacity has held back wider use. Their answer is a network of production sites close to the clinical centres that need the isotope. Ekalia chief executive Bruno Scutnaire said the technology was designed to put production where it is needed. "IBA's specialised alpha-beam cyclotron technology is designed to enable reliable astatine-211 production at the point of need. Building on our work with Framatome in Europe, Telix's U.S. infrastructure enables us to move faster towards establishing our first U.S. production unit, while laying the foundations for Ekalia's broader development in the country." The deal brings the IBA-Framatome partnership, set up in Europe to produce astatine-211 at industrial scale, into the US. Each company brings something different. IBA supplies the cyclotron technology and Framatome its nuclear and isotope production expertise. Telix contributes its US radiopharmacy network and "last-mile" distribution, along with its clinical portfolio and drug development capability.

Yahoo Finance

Oct 19th, 2026

Telix and Ekalia team up to produce astatine-211 in the US for cancer therapy

Telix Pharmaceuticals and Ekalia, a joint venture between IBA and Framatome, will collaborate on US production of astatine-211, an alpha-emitting isotope being studied for targeted alpha therapy. They announced the deal on October 19, 2026. The first IBA alpha-beam cyclotron will be installed at Telix's RLS Radiopharmacies site in Trevose, near Philadelphia. The parties may add more RLS sites as demand grows. The deal gives Telix long-term, priority access to the isotope for its alpha therapy pipeline, including TLX102-Tx, a candidate for glioblastoma and leptomeningeal disease. It will also supply third-party academic and industry programmes. Astatine-211 is promising, but limited production capacity has held back wider use.

Yahoo Finance

Oct 18th, 2026

Three Australian growth stocks with insider backing: PDI Gold, Telix and Codan

Simply Wall St has picked three Australian growth stocks with high insider ownership: PDI Gold, Telix Pharmaceuticals, and Codan. The screen favours fast growers that can handle higher costs as US inflation keeps interest rate risks in focus. PDI Gold (market cap A$4.3 billion) runs the Kiniéro Gold Mine in Guinea. Its reliance on oxide ore could lift costs and squeeze margins once that phase ends. Telix Pharmaceuticals (A$5.3 billion) develops radiopharmaceutical imaging agents and cancer therapies. Its imaging products brought in $803.8 million (USD) in the 2025 financial year, and growth hinges on its late-stage pipeline. Codan (A$11.4 billion) makes radio communications systems and metal detectors. Rising defence spending and demand for unmanned systems are expanding its order book.

Anderson Publishing, Ltd.

Oct 14th, 2026

Telix to present 20 abstracts at EANM 2026 Congress.

Telix to present 20 abstracts at EANM 2026 Congress. October 14, 2026 · News Release Telix has announced that it will be presenting 20 company-related abstracts at the forthcoming 39th Annual Congress of the European Association of Nuclear Medicine (EANM) scheduled for October 17-21, 2026, in Vienna, Austria. Dr. David N. Cade, Chief Medical Officer of Telix, emphasized that the company's robust presence at the event showcases the extensive development of its pipeline, which includes important therapeutic studies, precision diagnostics, and advanced technologies. He noted that the inclusion of 12 abstracts in top-rated oral presentations is a significant acknowledgment of the quality and clinical relevance of Telix's research. A symposium focusing on the future of theranostics in urologic oncology is also planned. Key presentations will feature pivotal trials such as the Phase 3 IPAX BrIGHT trial of TLX101-Tx in recurrent glioblastoma, the Phase 3 LUTEON trial of TLX250-Tx in clear cell renal cell carcinoma (ccRCC), and interim results from the PTherpan-Lu trial of TLX597-Tx in metastatic androgen pathway modulation-resistant prostate cancer (mAPMR). The event will also highlight topline Phase 3 data for TLX591-Px (Illuccix) PET imaging in prostate cancer among Chinese men, as well as real-world applications of TLX250-Px (Zircaix) in ccRCC. Additionally, Telix will sponsor the EANM Sanjiv Sam Gambhir Young Investigator Award to honor the legacy of the esteemed educator. Attendees can visit booth #527 to learn more about collaboration opportunities involving Illuccix(R), the PSMA-PET imaging agent, along with contributions from Telix's theranostic pipeline and innovative medical technologies, including the SENSEI(R) miniature drop-in gamma probe and QDOSE(R) dosimetry software. Sponsored symposium details. Title: The future doesn't wait: The next era of theranostics in urologic oncology. Date & Time: 18-Oct-26, 13:15 - 14:45 Location: Hall F2, Austria Center Vienna Chair: J. Calais, Gustave Roussy, IGR and Université Paris-Saclay, Paris, France * The theranostic revolution * The evolving role of PSMA-PET in prostate cancer * Next-generation PSMA therapeutics: Overcoming today's challenges * Panel discussion * Extending prostate cancer theranostic success to broader GU diseases Selected oral presentations. * ELEGANCE: Prospective pilot study assessing imaging performance of TLX250-Px in patients with hepatocellular carcinoma, biliary tract cancer or gastro-enteropancreatic neuroendocrine neoplasms. * * Date and Time: 18-Oct-26, 08:00 - 09:30 * Presenter: Clement Bailly * HIMIKO: TLX591-Px PET/CT in hepatocellular carcinoma. * * Date and Time: 18-Oct-26, 08:00 - 09:30 * Presenter: Rachel Bardy * Exploring carbonic anhydrase IX as a diagnostic imaging target using TLX250-Px in Von Hippel-Lindau Disease. * * Date and Time: 18-Oct-26, 15:00 - 16:30 * Presenter: Fabrizia Gelardi * LUTEON: Phase 3 study assessing safety and efficacy of TLX250-Tx in advanced ccRCC. * * Date and Time: 18-Oct-26, 15:00 - 16:30 * Presenter: Ghoufrane Tlili * Building the traceability backbone for radiopharmaceutical therapy: First results from the PDIB Secondary Standards Laboratory Network. * * Date and Time: 19-Oct-26, 08:00 - 09:30 * Presenter: Steven Graves With the exception of Illuccix, all products mentioned are investigational and have not received marketing authorization in any jurisdiction. More in theranostics. October 15, 2026 October 6, 2026

Telix Pharmaceuticals

Territory Account Manager

About the job